FDA Clears Gain Therapeutics' Parkinson's Drug GT-02287 for Phase 2 Study
GANX sits 52% above its 52-week low of $1.41.
Summary
Gain Therapeutics received FDA clearance for its Investigational New Drug (IND) application for GT-02287, allowing the Parkinson's disease treatment to advance into Phase 2 development. This positive regulatory step follows the interim positive Phase 1b data for GT-02287 reported on May 26th. Advancing a drug into Phase 2 is a critical de-risking milestone for a clinical-stage biotech, providing a much-needed positive development given the company's recent 10-Q filing which highlighted significant financial challenges and a going concern warning.
At the time of this announcement, GANX was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.5M. The 52-week trading range was $1.41 to $4.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.